Disease: Carcinoma of lung ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis. 12460919 2002
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE Although >90% of BRAF mutations in melanoma involve codon 599 (57 of 60), 8 of 9 BRAF mutations reported to date in NSCLC are non-V599 (89%; P < 10(-7)), strongly suggesting that BRAF mutations in NSCLC are qualitatively different from those in melanoma; thus, there may be therapeutic differences between lung cancer and melanoma in response to RAF inhibitors. 12460918 2002
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells. 31711466 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. 30224342 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE Consistent with earlier reports, our results show that KRAS and BRAF mutation frequencies in colorectal cancer were 44.3% and 13.0%, respectively, while EGFR mutations were detected in 11.1% of the lung cancer specimens. 21943394 2011
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. 28203297 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. 22649091 2012
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation. 27863474 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 Biomarker disease BEFREE BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. 29723688 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE These data, together with the nonoverlapping pattern of EGFR and BRAF mutations in human lung cancer, suggest that these lesions define distinct clinical entities whose treatment should be guided by prospective real-time genotyping. 19010912 2008
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. 24035431 2013
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 AlteredExpression disease BEFREE Recent evidence shows that BRAF-activated non-coding RNA (BANCR) acts as a critical role in the proliferation and metastasis in malignant melanoma and lung cancer; however, little is known about the significance of lncRNA BANCR in retinoblastoma. 25894373 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 Biomarker disease BEFREE Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. 24550319 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF gene mutations. 25153497 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of non-small cell lung carcinomas (NSCLC). 28625649 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma. 21483012 2011
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 Biomarker disease BEFREE A group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for <i>EGFR</i>, anaplastic lymphoma kinase (<i>ALK</i>), <i>ROS1</i>, <i>BRAF V600</i> and programmed death-ligand (PD-L1) at the time of diagnosis of advanced disease and <i>EGFR T790M</i> upon progression. 29507487 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 Biomarker disease BEFREE One of our predicted biomarker pairs, a mutation in the BRAF gene and upregulated expression of the PIM1 gene, was experimentally validated to benefit from a therapy combining BRAF inhibitor and PIM1 inhibitor in lung cancer. 26916442 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 Biomarker disease BEFREE The novel BRAF Thr599dup gene mutation, for which the repeat amino acid-tyrosine is inserted between the 599th amino acid and the 600th amino acid in exon 15 of BRAF, was identified by next-generation sequencing (NGS) during routine clinical care in a lung carcinoma sample from an Asian never-smoker. 30019008 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE We conducted a retrospective multicenter cohort study in Europe of patients with advanced BRAF-mutant lung cancer treated with known BRAF inhibitors. 26200454 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE ATM loss also enhances the sensitivity of KRAS- or BRAF-mutant lung cancer cells to MEK inhibition. 27922010 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 Biomarker disease BEFREE Jointly, our results suggest a potential role of the novel BRAF fusion in lung cancer development and therapy. 25985019 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. 27834212 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE The role of KRAS and BRAF mutations and ALK rearrangement in lung cancer-targeted therapy, are also reviewed. 21463141 2011
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.700 GeneticVariation disease BEFREE V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies. 25706985 2015